Despite languishing, pharma among top bets for DSP MF: Vinit Sambre
Despite being a defensive bet, pharmaceutical stocks have languished in 2022 primarily because of challenges like the poor pricing environment in the US, cross-currency fluctuations, and skyrocketing raw material prices. The sector still remains among the top bets for DSP Mutual Fund. “The demand here is almost non discretionary in nature, with a long runway … Read more